Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Verseon

  • Adityo Prakash, Verseon

Verseon is a clinical stage company that uses a computer-driven drug discovery platform to design, atom by atom, new drug candidates that are unlikely to be found by conventional methods. Our current drug programs include precision oral anticoagulants, oral drugs for diabetic macular edema and hereditary angioedema, and next-generation chemotherapy agents.

As part of our mission to develop disruptive technologies and products that advance global health, we are rethinking how drug development is funded. Security token offerings (STOs) provide a new, attractive way for companies to raise money and share their successes with a global investor community. However, the major obstacle to widespread adoption of securities transactions n the blockchain has been the enforcement of regulations of all countries involved. Through our subsidiary BlockRules Ltd., we are building the key missing piece of technology that allows the transition of securities issuance and trading on the blockchain.

  • Date:Tuesday, February 12
  • Time:9:15 AM - 9:30 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23552
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Present a novel investment platform for life-sciences companies to reach a global investor base.
  • Company Website:www.verseon.com
  • Company HQ City:Fremont
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:VSN
  • Exchange:LSE
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development:Precision Oral Anticoagulant
  • Development Phase of Primary Product:Phase I
Speakers
Adityo Prakash
Verseon
Back